CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MZT Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MZT Holdings, Inc.
124 Washington Street
Suite 101
Phone: (508) 203-4286p:508 203-4286 Foxborough, MA  02035  United States

This company was Merged or Acquired on 12/13/2007.
This company is no longer actively traded on any major stock exchange.

Business Summary
MZT Holdings, Inc., formerly Matritech, Inc., is a biotechnology company principally engaged in the development, manufacture, marketing, distribution and licensing of cancer diagnostic technologies and products. The products it has developed are based on its nuclear matrix protein (NMP) technology. Its first two products, the NMP221 Test Kit and NMP22 BladderChek Test, sales of which represent approximately 91% of the Company’s total revenue for the year ended December 31, 2006, are designed to detect the presence of a specific protein marker in urine correlated with the presence of bladder cancer. The Company’s sales of the NMP22 BladderChek Test are concentrated in the United States and Germany, where its own sales forces sell the NMP22 BladderChek Test directly to prescribing physicians. It has discovered other proteins associated with cervical, breast, prostate and colon cancer. In December 2007, Inverness Medical Innovations, Inc. acquired Matritech, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/200712/31/2006YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Treasurer, Secretary Craig R.Jalbert 47 1/18/2008 12/12/2007
Chief Financial Officer, Vice President - Finance, Assistant Secretary Richard A.Sandberg 66 3/19/2008 4/1/1999
President of Matritech GmbH FranzMaier 55 6/1/2003 6/1/2003
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Matritech, Inc.
MZTH

General Information
Outstanding Shares: 62,200,272 (As of 11/6/2007)
Shareholders: 9,400
Stock Exchange: OTC
Federal Tax Id: 042985132


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023